Material
T umor vaccines have great potential for treating malignant tumors due to their activation and expansion of tumorspecific T cells that can recognize and kill target tumor cells. The presumption that T cell priming is insufficient has led to intensive efforts to improve immunization strategies including peptide-based (1), dendritic cell-based (2), and gene-based tumor vaccines (viral vectors and DNA) (3, 4) . We and others previously found that cutaneous immunization with lentivector (lv) could effectively transduce skin dendritic cells and stimulate potent Ag-specific CD8 T cell responses (5) (6) (7) (8) (9) . We further showed that lv expressing self-tumor Ag, tyrosinase related protein 1 (TRP1), induced potent CD8 T cell responses and markedly increased tumor-infiltrating lymphocytes (TILs) into B16 tumors (10) . However, despite intensive efforts, the therapeutic antitumor efficacy of vaccine-based immunotherapy in treating established tumors is limited (11) . Reports on human cancer patients also found that the tumors continued to grow despite the presence of high numbers of tumor-specific T cells (12) (13) (14) (15) . These findings suggest that the established tumor microenvironment is potently and dominantly immune suppressive and that the effector functions of CD8 TILs may be impaired (16) (17) (18) (19) . Indeed, multiple suppressive mechanisms including regulatory T cells (Tregs) (20) (21) (22) and myeloid-derived suppressor cells (MDSCs) (18, 23) were reported to inhibit the function of T effector (Teff) cells. In addition to these extrinsic immune-suppression mechanisms, the latest studies showed that CD8 TILs expressed programmed death-1 (PD-1) (24, 25) , which was implicated in tumor evasion (26, 27) and contributed to immune suppression in the tumor microenvironment (28) .
Although the current efforts toward tumor vaccines are focused on improving the magnitude of tumor-specific Teff cells, scant attention has been paid to studying how immunization will affect the immune-suppressive tumor microenvironment and whether vaccine-activated T cells can retain their effector function after entering into tumor lesions. Although lv immunization stimulates potent T cell immune responses, it is not clear what effect lv immunization will have on immune suppression in the tumor microenvironment. The fact that potent systemic CD8 T cell responses and marked increase of TILs after lv immunization are unable to eradicate established tumors (10) prompts us to hypothesize that immunization fails to relieve immune suppression in the tumor lesions and that the effector function of CD8 T cells in the tumor microenvironment may be compromised. To test this hypothesis, in the current study we investigated the immunological changes including the immune effector and regulatory cells in the tumor microenvironment after lv immunization and whether measures of tackling the immune-suppression mechanisms would enhance the antitumor efficacy of lv immunization. We found that lv immunization markedly increased the tumor infiltration of CD8 and CD4 Teff cells but also attracted more Tregs and MDSCs into the tumor lesions. In addition, immunization increased programmed deathligand 1 (PD-L1) expression on both tumor cells and leukocytes in the tumor lesions. Furthermore, CD8 TILs expressed a high level of PD-1 and low amounts of IFN-g and TNF-a and were compromised on degranulation. These data demonstrate that multiple immune suppression mechanisms dominate the tumor microenvironment and that immunization may further accentuate the suppressive tumor microenvironment by attracting more MDSCs and Tregs to tumor lesions and by increasing PD-1/PD-L1 engagement. Blockade of the PD-1 signaling partially recovered the effector functions of TILs and enhanced the antitumor efficacy of lv immunization, providing a strong rationale for the combinatorial tumor immunotherapy of integrating immunization strategies with approaches of diminishing immune suppression in the tumor microenvironment to achieve effective therapeutic antitumor effect.
Materials and Methods

Cell lines, mice, and tumor growth
The B16F10, MO4 (OVA expressing B16F10) tumor cells, and 293T cells were cultured in DMEM medium. Pmel-1 TCR transgenic mice were purchased from The Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were obtained from the National Cancer Institute (Frederick, MD) and The Jackson Laboratory. All the mice were housed under specific pathogen-free conditions at Laboratory Animal Services of the Medical College of Georgia. Animal care protocols were approved by the Institutional Animal Care and Use Committee of the Medical College of Georgia.
To establish tumors, B16F10 cells (1 3 10 5 ) and MO4 cells (2 3 10 5 ) were inoculated s.c. into the shaved flank of C57BL/6 mice.
Viral vector preparation and immunization
OVA-lv and TRP1-lv lvs and OVA-adenoviral vector (Ad) were prepared as previously described (5, 6, 10) . Lv expressing melanoma Ag, human gp100 (hgp100) Ag, was constructed by replacing the TRP1 gene with hgp100 gene. Lvs were prepared and titered as we previously described (10) . For immunization, TRP1-lv, hgp100-lv, and OVA-lv were injected via footpad at doses of 2.5 3 10 7 , 1.5 3 10 7 , and 3 3 10 6 transduction units, respectively. Twenty million PFU of OVA-Ad were used for immunization to elicit similar magnitude of CD8 responses as 3 3 10 6 transduction units of OVA-lv. All immunization was conducted 5 d after tumor inoculation when tumor lesions were clearly visible. Volumes of 50 ml were used in all experiments.
Adoptive cell transfer
TCR transgenic hgp [25] [26] [27] [28] [29] [30] [31] [32] [33] specific Pmel-1 T cells were isolated from transgenic mice by magnetic beads (Miltenyi, Auburn, CA). Because the precursor frequency affect the effector function and quality of immune responses (29) , an optimal dose of 0.5 million to 1.0 million pmel-1 cells was injected into mice 1 d prior to tumor inoculation.
Abs, cell separation, intracellular staining, and flow cytometry
The Abs used in this study, anti-CD45, anti-CD90.2 (Thy1.2), anti-CD8, anti-CD4, anti-CD11b, anti-Gr-1, anti-CD107a, anti-PD-1, anti-PD-L1, antiFoxP3, anti-IFN-g, and anti-TNF-a, were purchased from BD Biosciences (San Diego, CA), Biolegends (San Diego, CA), and eBioscience (San Diego, CA).
Tumors were collected and weighted, and single-cell suspensions were prepared (10). Briefly, 10-100 mg tumor was cut into small pieces and incubated at 37˚C for 0.5 h in RPMI 1640 containing 1 mg/ml collagenase, 1 mg hyaluronidase, and 100 U DNase I. All enzymes were from Sigma (St. Louis, MO). To isolate Tregs and MDSCs, tumor cell suspensions were loaded onto Percoll gradient (GE Healthcare, Piscataway, NJ).
Enriched lymphocytes were isolated by cell sorting (FACSAria, BD Biosciences).
To measure cytokines, cells were stimulated with peptides in vitro for 3 h in the presence of GolgiStop (BD Biosciences) as described (10) . For some experiments, aPD-L1 (clone 10F.9G2 from BioXcell, West Lebanon, NH) and aPD-1 (clone RMPI-14) (30) Abs were added to a final concentration of 1 mg/ml. Intracellular staining of IFN-g and TNF-a was performed (6) . Alternatively, to measure the extent of degranulation, antiCD107a Ab was added to the ex vivo cell culture as described (31) . Cells were collected using a FACScanto (BD Biosciences). Data were analyzed using FCS Express V3 software (De Novo Software, Los Angeles, CA).
To study the effect of PD-1 and PD-L1 blockade on the antitumor efficacy of lv immunization, 200 mg aPD-L1 and aPD-1 or rat IgG isotype control Abs were injected into mice i.p. on the same day of immunization and continued every other 2 d.
In vitro inhibition of T cell proliferation by Tregs and MDSCs
Inhibition of T cell proliferation by Tregs and MDSCs was conducted as described previously (32) . Briefly, 50,000 magnetic bead-isolated CD4 T cells were labeled with 0.1 mM CFSE and then cocultured with 10,000 CD11c + dendritic cells (isolated by magnetic beads) with or without 50,000 sorted MDSCs or Tregs in the presence of 0.5 mg/ml CD3 Ab. After 72 h, CD4 T cell proliferation was determined by the dilution of CFSE using flow cytometry analysis.
Statistical analysis
The statistical significance of the experimental data were analyzed using unpaired two-tailed t test (GraphPad Software, La Jolla, CA).
Results
Tumor infiltration of CD4 and CD8 T cells after lv immunization is Ag dependent
We previously found that lv TRP1-lv immunization markedly increased T cell infiltration into tumor lesions and inhibited tumor growth (10) . To study whether the T cell infiltration was Ag driven and dependent, we established both B16F10 and MO4 tumors in the same mice, which were then immunized with either TRP1-lv or OVA-lv. Both TRP1-lv and OVA-lv stimulated potent CD8 T cell responses, and IFN-g + CD8 T cells could be detected in the peripheral blood of immunized mice (Fig. 1A) . To achieve similar magnitude of CD8 T cell responses, ∼8-10 times more TRP1-lv than OVA-lv was used. When the TIL was analyzed, we found that infiltration of CD4 and CD8 T cells in B16F10 tumor lesions was markedly increased by TRP1-lv but not by OVA-lv (Fig. 1B, 1C) . On average, CD8 T cell infiltration increased 15-fold compared with 8-fold increase of CD4 T cells after TRP1-lv immunization. In contrast, both TRP1-lv and OVA-lv lv increased CD8 and CD4 T cell infiltration into MO4 tumors (Fig. 1B, 1C ) because MO4 tumors express both TRP1 and OVA Ag. Consistent with the tumor infiltration data, B16F10 tumor growth was strongly inhibited by TRP1-lv but not by OVA-lv immunization, and the B16F10 tumor masses were significantly smaller in the mice treated with TRP1-lv than in those of control or OVA-lv treated mice (Fig. 1D) . Not surprisingly, the antitumor effect of TRP1-lv immunization was found in both B16F10 and MO4 tumor models, whereas OVA-lv was only able to inhibit growth of MO4 tumors but not the parental B16F10 (Fig. 1D ). These data strongly indicate that lv immunization induces Ag-dependent T cell infiltration and tumor growth inhibition.
Accumulation of MDSCs and Tregs in B16 tumor lesions is accentuated by lv immunization in an Ag-dependent manner
To investigate the dynamic changes of immune suppression in tumor lesions, Tregs and MDSCs were analyzed at different time points after inoculation of B16F10 tumor cells. In 5-d tumor lesions, ∼14% of the CD4 TILs was Tregs, whereas 12% of the non-T leukocytes (CD45 + Thy1.2 2 ) was CD11b + Gr-1 + MDSCs (Supplemental Fig. 1 ). By day 12 after tumor inoculation, ∼30% of CD4 TILs was Tregs, and 50% of non-T leukocytes was MDSCs. The data demonstrate that the MDSCs and Tregs are accumulated rapidly in the tumor lesions.
Then, the impact of lv immunization on the accumulation of MDSCs and Tregs in the tumor lesions was studied. Lv immunization did not alter percentage of MDSCs in the tumors. But, the absolute number of MDSCs in B16 tumor was markedly increased (∼6-fold) by TRP1-lv (but not OVA-lv) immunization ( Fig. 2A) due to the influx of leukocytes. Similarly, the absolute number of Tregs in B16 tumor increased ∼5-fold by TRP1-lv (but not by OVA-lv) immunization even though the percentage of Tregs was significantly reduced (Fig. 2B ). On the other hand, MDSC and Treg accumulation in the MO4 tumor lesions was found after both TRP1-lv and OVA-lv immunization (Fig. 2C) , consistent with the Ag-dependent Teff cell tumor infiltration (Fig. 1B, 1C ). These data suggest that the increase of tumor infiltration of MDSCs and Tregs may be related to the expression of tumor Ag but not lv per se. In agreement with this hypothesis, OVA-Ad, immunization also increased MDSC and Treg accumulation in the MO4 tumor lesions (Fig. 2D) .
Compared with the MDSCs and Tregs in the tumor lesions, which can reach 50 and 30%, respectively, spleen contained a significantly lower level of MDSCs (∼10%) and Tregs (∼8%). Whereas tumor growth moderately increased MDSCs and Tregs The Journal of Immunologyin the spleen, immunization did not cause further increase of accumulation (Supplemental Fig. 2) .
The function of MDSCs and Tregs that accumulated in the tumor lesion was determined by their in vitro inhibition of CD4 T cell proliferation. Addition of MDSCs or Tregs strongly inhibited aCD3-stimulated CD4 T cell proliferation (Fig. 2E) , suggesting that MDSCs and Tregs from tumor lesions of lv-immunized mice were immune suppressive.
The above data indicate that lv immunization markedly increases tumor infiltration of effector CD8 and CD4 T cells (Teff cells), but also increases the absolute number of suppressive MDSCs and Tregs in the tumor lesions. To better understand the immune balance in the tumor lesions after immunization, we calculated the ratios of CD8/MDSC, CD8/Treg, and CD4 Teff cells/Treg in the tumor lesions. Lv TRP1-lv immunization increased the ratios of Teff cells over MDSCs and Tregs in the tumor lesions (Supplemental Fig. 3) . Thus, the data demonstrated that tumor infiltration by immune Teff cells is more pronounced than that by MDSCs and Tregs, which may explain why lv immunization did inhibit tumor growth.
PD-1 is increasingly expressed on TILs, and PD-L1 is induced in the tumor lesions by lv immunization
We hypothesized that in addition to the above extrinsic suppressive components of Tregs and MDSCs, tumor-infiltrating immune effector cells may be intrinsically dysfunctional in the tumor microenvironment. One of the intrinsic mechanisms of immune dysfunction occurs via the PD-1/PD-L1 pathway (33). Lv immunization markedly increased the TILs in the tumor lesions (Fig. 1) . However, TILs are exposed to high concentration of tumor Ag for a prolonged period of time, which can lead to the upregulation of PD-1. Indeed, the expression of PD-1 on CD8 TILs progressively increased and paralleled the tumor growth (Fig. 3A) . By day 19, CD8 TILs began to show modest increase of PD-1 expression, and in day-26 tumors, there was a substantial elevation in the PD-1 levels on CD8 T cells. In addition, there was a correlation between PD-1 expression and the size of the tumor (Fig. 3B) . For example, ∼40% of CD8 TILs were found to be PD-1 + in a small 30 mg tumor; whereas PD-1 + CD8 TILs in a larger 168 mg tumor reached 60%. However, immunization did not further change the proportion of PD-1 + CD8 T cells and the level of PD-1 (Fig. 3A) . In contrast with the marked increase of PD-1 on TILs, no obvious PD-1 elevation was found on the spleen CD8 T cells.
We next investigated the effect of lv immunization on the induction of PD-L1 expression in the tumor lesions as the PD-1/PD-L1 engagement could induce apoptosis of T cells and protected tumor cells from being killed by CTLs (26, 34) 
2 ) all expressed low-level PD-L1 (Fig. 3C) . Lv immunization increased PD-L1 expression (percentage and intensity) on all three populations of cells in the tumor (Fig. 3C) . On the other hand, immunization had little effect on the spleen cell PD-L1 expression. The mechanism of immunization-induced PD-L1 expression is not clear. However, it has been reported that IFN-g treatment could activate PD-L1 gene expression (35) . Indeed, while the cultured B16F10 cells were PD-L1 negative, IFN-g treatment dramatically increased PD-L1 expression (Fig. 3D) . Thus, it is likely that the CD8 TILs in the tumor lesions produce IFN-g in responses to tumor Ag, which increases PD-L1 expression on the tumor cells and TILs.
The effector function of CD8 TILs is severely compromised
Accumulation of Tregs and MDSCs in the tumor lesions and the increased PD-1/PD-L1 engagement suggest that the function of the CD8 TILs may be compromised in the tumor lesions. The production of multiple effector cytokines, such as IFN-g and The Journal of ImmunologyTNF-a, is a well-established indicator of activated T cell function after microbial infection, and it has been suggested that failure to produce multiple cytokines may be related to the stage of exhaustion (36, 37) . A much higher percentage of CD8 TILs (∼8%) than spleen CD8 T cells (∼3%) produced IFN-g in responses to brief ex vivo stimulation with TRP1 peptides, suggesting that Ag-specific CD8 T cells were preferentially attracted to tumor lesions (Fig. 4A, 4B) . However, only ∼20% of IFN-g + CD8 TILs was also TNF-a + (Fig. 4A, 4C ). By contrast, ∼60% of IFN-g + CD8 T cells in spleen were also producing TNF-a. Furthermore, the amount (as reflected by the mean fluorescent intensity [MFI]) of IFN-g and TNF-a produced by CD8 TILs was significantly lower than that produced by the spleen CD8 T cells (Fig. 4D) . Because the level of CD107 on the cell surface after Ag stimulation is correlated to the cytolytic function of CD8 T cells (38) , we also investigated the degranulation of CD8 TILs by using CD107a as a marker of the cytotoxic activity of CD8 T cells (31) . Consistent with the results obtained from cytokine staining, although a higher percentage of CD8 T cells in tumor lesions were capable of degranulation (CD107a + ; Fig. 4A ), the extent of degranulation (MFI of CD107a) of the tumor CD8 TILs was significantly lower than that of the spleen CD8 T cells (Fig. 4D ). This suggests that, compared with spleen CD8 T cells, the degranulation (cytolytic activity) of CD8 TILs is also inhibited.
Because there is no reliable tetramer for staining TRP1-specific CD8 T cells, we used the adoptive transfer of TCR transgenic pmel-1 CD8 T cells (39) into C57BL/6 mice to more precisely compare the functional changes of Teff cells between the spleen and tumor by gating on a defined cell population. Adoptive transfer of pmel-1 cells was conducted 1 d prior to B16 tumor inoculation to allow habitation of exogenous T cells in the mice. Immunization with lv hgp100-lv was conducted 5 d after tumor cell inoculation. Cytokine production by spleen and tumor pmel-1 cells was examined 15 d later. As demonstrated in Fig. 4E , although the percentage of IFN-g-producing pmel-1 cells remained high, the pmel-1 cells capable of producing multiple cytokines was markedly reduced in the tumor lesions. The loss of TNF-a production was especially dramatic in the TILs (Fig. 4E) . Thus, the adoptive transfer study confirms that the effector function of CD8 TILs is severely compromised in the tumor microenvironment.
To demonstrate further that the loss of effector function was indeed because of the inhibition of the tumor microenvironment, splenocytes containing the pmel-1 cells were cocultured with tumor cell suspension together during ex vivo restimulation. In the presence of total cells of tumor lesions, the spleen pmel-1 cells capable of producing multiple cytokines, especially the TNF-a, was significantly decreased (Fig. 4F) , suggesting that the cellular components of tumor lesions could rapidly inhibit the effector function of CD8 T cells. It also implies that when effector T cells enter the tumor microenvironment, their function will be immediately inhibited.
The effector function of CD8 TILs can be partially rescued by PD-1/PD-L1 blockade in vitro
The above study showed that CD8 T cell function is partially lost after migrating into tumor lesions. Although all different immunesuppressive components identified above in the tumor lesions can contribute to the loss of effector function of TILs, it is impractical or impossible to remove all the components from the tumor lesions. Because immunization further increases the expression of PD-L1 in the tumor lesions and the PD-1/PD-L1 pathway can be the common immunosuppressive mediator of different cellular components, we studied the possibility of rescuing the effector function of CD8 TILs by PD-1/PD-L1 blockade in vitro. Consistent with that in Fig. 4E , the percentage of IFN-g and TNF-a double-positive pmel-1 cells from the tumor was significantly lower than that in the spleen. Importantly, the reduced effector function of TIL pmel-1 was partially recovered after treatment with PD-1 and PD-L1 blocking Abs in vitro (Fig. 5) , suggesting that the lost effector function of TILs can be partially rescued.
In vivo PD-1/PD-L1 blockade rescues the effector function of TILs and improves the antitumor efficacy of lv immunization
Next, we studied the possibility of rescuing the effector function of CD8 TILs in vivo by blocking the PD-1/PD-L1 engagement using PD-1 and PD-L1 Abs. Mice bearing 5 d B16F10 tumors were immunized with TRP1-lv and treated with aPD-1 and aPD-L1 Abs or control isotype Ab. Compared with the mice injected with isotype Ab, injection of PD1 and PD-L1 Abs markedly increased the effector functions of CD8 TILs (Fig. 6A) . Frequency of IFN-g + , IFN-g + TNF-a + , IFN-g + CD107a + CD8 T cells were all significantly increased. In addition, the antitumor efficacy of TRP1-lv immunization was markedly enhanced by administration of PD1 and PD-L1 Abs (Fig. 6B) . The tumor weight at the end of experiment also showed that PD-1 and PD-L1 Abs significantly improved the antitumor efficacy of TRP1-lv immunization (Fig. 6C) . The likely mechanism for rescuing the effector function is via direct blockade of PD1 signaling on CD8 TILs. However, because the PD-L1 expression was found to regulate development of Tregs (40, 41), we analyzed the effect of in vivo PD-1/PD-L1 blockade on the prevalence of MDSCs and Tregs in the tumor lesions. The data showed that PD-1/PD-L1 blockade further reduced the percentage of Tregs (Fig. 6E) in the tumor lesions even though it has little effect on the frequency of MDSCs (Fig. 6D) . Thus, it is likely that PD-1/ PD-L1 blockade may also indirectly enhance the effector function of CD8 TILs by reducing the Treg-mediated inhibition in the tumor lesions.
To more specifically analyze the in vivo recovery of effector function by PD-1/PD-L1 blockade, we injected pmel-1 CD8 T cells into B16 tumor-bearing mice before immunization and PD-1 and PD-L1 Ab injection. Consistent with data of Fig. 4E , the production of both IFN-g and TNF-a effector cytokines by pmel-1 cells were significantly reduced in the tumor lesions compared with that in the spleen (Fig. 7A) . The degranulation of pmel-1 was also markedly reduced (Fig. 7B) . Importantly, in vivo administration of PD-1 and PD-L1 Abs partially recovered the function of pmel-1 (Fig. 7A,  7B ). The frequency of IFN-g + , IFN-g + TNF-a + , IFN-g + CD107a + in the CD8 TILs increased from ∼30, ∼7, and 20% to ∼50, ∼15, and ∼40%, respectively (Fig. 7D) . But the effector function was never fully recovered to the level of the CD8 cells in the spleen (Fig. 7C) . The increase of effector function of CD8 TILs was accompanied by improved antitumor efficacy of lv hgp100-lv immunization (Fig. 7E) . The tumor weight at the end of the experiments also reflected the better antitumor effect of hgp100-lv immunization by PD-1 and PD-L1 Abs (Fig. 7F) . Compared with data in Figs. 1D and 6C, the slightly lower tumor weight (though statistically insignificant) in the control group was possible due to the adoptive transfer of TCR transgenic pmel-1 cells (Fig. 7F) . In summary, these data suggest that in vivo PD-1/PD-L1 blockade can recover part of the lost effector function of CD8 TILs in the tumor microenvironment and markedly enhanced the antitumor efficacy of lv immunization.
Discussion
The aim of this study is to elucidate the effect of lv immunization on the cellular immune-suppressive components in a tumor microenvironment and to study whether the effector function of TILs can be rescued to enhance the antitumor efficacy of lv immunization. We found that lv immunization markedly increased tumor infiltration of CD8 and CD4 Teff cells but also increased the absolute number of immune-suppressive cells (MDSCs and Tregs) in the tumor lesions. The effector function of CD8 TILs was severely compromised possibly by the extrinsic MDSCs and Tregs and by the intrinsic PD-1/PDL1 engagement. Blockade of PD-1 and PD-L1 partially rescued the effector function of CD8 TILs both in vitro and in vivo and significantly enhanced the antitumor efficacy of lv immunization.
The tumor microenvironment is highly immune suppressive (23) . In this study, we showed that immune suppression in tumor lesions was rapidly established as early as day 5 after tumor inoculation (Supplemental Fig. 1 ). When the mice bearing 5-d B16 tumors are immunized with lv, it takes another week before Teff cells are expanded to a measurable level (5) . By this time, the Fig. 2A, 2B ) and the inhibitory PD-1/PD-L1 engagement (Fig. 3) ; thus, the established suppressive conditions in the tumor lesion were reinforced after immunization, resulting in marked decrease of cytokine production by CD8 TILs (Figs. 4, 7A) . Thus, even though lv immunization stimulated more Teff cell infiltration (10-to 15-fold increase of effector CD8 T cells versus 5-to 6-fold increase of Tregs and MDSCs), only limited antitumor efficacy was observed. The accumulation of more MDSCs and Tregs in the tumor lesion is due to the lv per se as Ad immunization stimulated similar effect (Fig. 2D) .
Tumor vaccines are intended to activate and expand tumor Ag specific T cells, which then infiltrate into tumor lesions because of the abundant tumor Ags in the tumor microenvironment. But it is less intuitive to comprehend that immunization causes the increased accumulation of MDSCs in the tumor lesions. It is unlikely that immunization will expand MDSCs. However, tumor growing increases MDSCs in the spleen. It is possible that MDSCs in the tumor may come from the circulation (42) and that the inflammatory cytokines/ chemokines produced by TILs increase the MDSC accumulation in the tumor lesion. Likely, the mechanisms of increasing Treg accumulation in the tumor lesions by immunization are not known. It is not clear if lv can stimulate Treg amplification as it was demonstrated in vaccinia vector immunization (43) . However, MDSCs in the tumor lesion may mediate Treg development in the tumor (44) , and PD-L1 expression that was induced in the tumor microenvironment was also found to regulate development of Tregs (40, 41) , suggesting that Tregs may be produced locally in the tumor lesions. Our data of PD-1/PD-L1 blockade decreasing Tregs in the tumor lesions (Fig. 6E) is consistent with this hypothesis. Furthermore, inflammation is commonly associated with most immunization formulations including recombinant viral vectors and can activate IDO (45) , which stimulates Treg activity in the tumor and tumor-draining lymph nodes (46) . Thus, it is possible that immunization may also trigger the IDO activity in the tumor microenvironment, which regulates the effectiveness of immune responses. But those mechanisms of immune regulation remain to be studied.
The CD8 TILs were capable of producing effector cytokine IFN-g but at reduced levels in the tumor lesions (Fig. 4) . These incompletely exhausted CD8 TILs may partially exert their function and mediate tumor killing (as they can degranulate; FIGURE 5 . In vitro PD-1/PD-L1 blockade partially recovers the lost effector function of CD8 TILs. Splenocytes and total cells of the tumor lesions were prepared from the tumor-bearing mice after pmel-1 adoptive transfer and hgp100-lv immunization. Cells were restimulated ex vivo with peptide in the presence or absence of PD1 and PD-L1 Abs. Cytokine production was determined by intracellular staining of IFN-g and TNF-a. A representative result with five mice is presented. (Fig. 3C) (35) . Although the accumulation of MDSCs and Tregs in the tumor lesions occurs at an early stage when the tumors are small (Fig.  2) , the expression of PD-1 on CD8 TILs requires a longer Ag exposure time and is dependent on the age and size of the tumor. This is consistent with the findings of a previous report, in which prolonged Ag exposure could increase the levels of PD-1 expression in chronic viral infections (47) . With the advancing growth of a tumor, the PD-1 expression on CD8 TILs (Fig. 3A,  3B ) and the induced expression of PD-L1 (Fig. 3C, 3D ) on tumor cells can result in stronger inhibitory engagement of PD-1/ PD-L1. This interaction could lead to the apoptosis of T cells (26) and/or prevention of the cytotoxic killing of tumor cells by Teff cells (34, 48) .
PD-1/PD-L1 blockade was previously demonstrated to potentiate therapeutic antitumor efficacy (34, 49) . In this study, we found that part of the improved antitumor efficacy may result from the recovered TIL effector function in the tumor lesions. Both in vitro and in vivo PD-1/PD-L1 blockade resulted in enhanced production of cytokines. In addition, the decrease of Tregs in the tumor lesions by PD-1/PD-L1 blockade (Fig. 6E ) may also help rescue the effector function of CD8 TILs. However, because the tumor lesions are also infiltrated with Tregs and MDSCs and soluble inhibitory factors (such as TGF-b and IL-10), it is no surprise that effector function of CD8 T cells was recovered only partially by PD-1/PD-L1 blockade, which further attests to the need of counteracting multiple immune-suppressive mechanisms existing in the tumor microenvironment.
In conclusion, in this study, we found that immunization with lv stimulated potent CD8 Teff cell responses and markedly increased the Teff cell infiltration into tumor lesions, resulting in potent antitumor effect. However, immunization also attracted more immune-suppressive cells such as MDSCs and Tregs into the established tumor microenvironment and increased inhibitory PD-1/PD-L1 engagement, which may limit antitumor efficacy of tumor vaccines. Blockade of PD-1/PDL1 signaling can partially rescue the effector function of CD8 TILs and enhance the antitumor efficacy of lv immunization. This study allows us to understand the effect of immunization on immune regulations in the tumor microenvironment but also implies that interference with the immune suppression can enhance the antitumor efficacy of tumor vaccines. The data provide a strong rationale for incorporating multiple approaches to reverse the immune suppressions in the tumor microenvironment, stressing the importance of combinatorial approaches for tumor immunotherapy to improve the antitumor efficacy of current immunization approaches (50, 51) .
